← Eichor
Condition: Ctla4 Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Ctla4

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Novel Genetic Disorders of the Immune System
Phase N/A · 1 location(s) · National Institute of Allergy and Infectious Diseases (NIAID · NCT02257892Iparomlimab and Tuvonralimab Combined With Apatinib and Irinotecan Hydrochloride for the Treatment of Advanced Alpha-fet
Phase 2 · 1 location(s) · Hebei Medical University Fourth Hospital · NCT07289997Cryoablation Combined With the Dual-Function Antibody PD-1/CTLA-4 for the Treatment of LAPC Following Failure of First-L
Phase 2 · 1 location(s) · Ruijin Hospital · NCT07306286A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors
Phase 1/Phase 2 · 33 location(s) · CStone Pharmaceuticals · NCT06741644Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC
Phase 2 · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT07447570GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression
Phase 1 · 2 location(s) · Second Affiliated Hospital of Guangzhou Medical University · NCT03198546Evaluation of Skin Health and QoL in Pts Receiving Anti-PD1/PDL1/CTLA4 or CDK Inhibitors.
Phase N/A · 1 location(s) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT05878964Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil for Advanced Cholangiocarcinoma
Phase 2 · 1 location(s) · West China Hospital · NCT06438822RC48 in Combination With AK104 and Bevacizumab in OCCC
Phase 2 · 1 location(s) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · NCT06540729Montreal Immune-Related Adverse Events (MIRAE) Study
Phase N/A · 1 location(s) · Sir Mortimer B. Davis - Jewish General Hospital · NCT05139706Exploratory Study of MSLN-CAR T Cells Secreting PD1/CTLA-4 Nanoantibody for the Treatment of Advanced Solid Tumors
EARLY_Phase 1 · 1 location(s) · Shanghai Cell Therapy Group Co.,Ltd · NCT06248697Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Second Affiliated Hospital of Guangzhou Medical University · NCT05187338Interferon Signature in Anti-CTLA-4 and Anti-PD-1/PD-L1-Treated Cancer Patients Compared With Systemic Autoimmune Diseas
Phase N/A · 1 location(s) · Hospital Universitario Araba · NCT07249060Neo-adjuvant Immunotherapy in Patients With Localized Melanoma
Phase 2 · 6 location(s) · UNICANCER · NCT07230613Analysis of T and B Cell Repertoire Changes in Response to Orencia® (Abatacept) in Rheumatoid Arthritis
Phase N/A · 1 location(s) · Hospital for Special Surgery, New York · NCT05782335SCRT(Short Course Radiotherapy) Combined With CAPOX Plus QL1706 for Rectal Cancer Liver Metastases
Phase 2 · 2 location(s) · Fujian Cancer Hospital · NCT06787183A Study of Botensilimab and Balstilimab for Colorectal Cancer With ctDNA+ After Surgery and Chemotherapy
Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT07227636A Trial of Cadonilimab With Adriamycin in Patients With Advanced Soft Tissue Sarcoma
Phase 2 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT06367075IRE Combined With the Dual-Function Antibody PD-1/CTLA-4 for the Treatment of LAPC Following Failure of First-Line AG Th
Phase 2 · 1 location(s) · Ruijin Hospital · NCT07306273QL1706 Combined With Chemotherapy in the Treatment of Immune-mediated NSCLC
Phase 2 · 1 location(s) · Anhui Provincial Cancer Hospital · NCT07330596Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors
Phase 1 · 1 location(s) · Second Affiliated Hospital of Guangzhou Medical University · NCT04842812Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.
Phase 2 · 1 location(s) · Second Affiliated Hospital of Guangzhou Medical University · NCT06492408Infusion of PD1/PDL1/CTLA4 Inhibitors Via Hepatic Arterial for Immunotherapy of Hepatocellular Carcinoma
Phase 3 · 1 location(s) · Second Affiliated Hospital of Guangzhou Medical University · NCT03949231VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
Phase 3 · 81 location(s) · Replimune, Inc. · NCT06264180Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patie
Phase 1 · 45 location(s) · BioNTech SE · NCT05142189QL1706 for the Neoadjuvant Treatment of HR+/HER2- Breast Cancer
Phase 2 · 1 location(s) · Henan Cancer Hospital · NCT06967103Cadonilimab in Patients (Pts) with Advanced Non-small Cell Lung Cancer (NSCLC)
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT06793813Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma
Phase 2 · 1 location(s) · Sarcoma Oncology Research Center, LLC · NCT03886311A Dose Escalation and Expansion Study of GIGA-564 in Participants With Locally Advanced or Metastatic Solid Tumor Malign
Phase 1 · 1 location(s) · GigaGen, Inc. · NCT06258304AK104 for Recurrent or Metastatic Vulvar Cancer
Phase 2 · 6 location(s) · Akeso · NCT05932212
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.